Skip to main content
Premium Trial:

Request an Annual Quote

PamGene Chair Steps Down; William Emhiser Goes to Proteome Systems; Thomas Ignolia Becomes Myriad Proteomics CEO; and Others

NEW YORK, June 11 - Pieter Strijkert is stepping down as chairman of PamGene's supervisory board, the Hertogenbosch, Netherlandscompany said today.

 

Jean Deleage, a major investor and board member of the microarray company since 2000, has been appointed interim chair.

 

Strijkert, who served as chairman of PamGene's board since February 2000, is also on the boards of Chiron and ParaTek Pharmaceuticals, and has chaired the supervisory board of Crucell. He has also held positions at Dutch organizations Philips Eindhoven, the Erasmus University Rotterdam and Gist brocades.

 

Deleage is a managing general partner and founding member of venture capital firm Alta Partners, which led PamGene's original $6.4 million equity financing round in December 2000.

 

Before joining Alta in 1996, Deleage was a managing partner of VC firm Burr, Egan, Deleage. He was a founding member of Sofinnova, which he founded in 1976. Deleage also holds board seats at Crucell, Rigel, Kosan Bioscience, and several private companies.


 

Peter Boatright and Tim McGrath have been appointed to serve on the board of Lark Technologies, a Houston-based genomic technology services firm, the company said today.

 

Boatright serves on the board of the Oklahoma United Methodist Foundation and Guaranty Credit Card, as well as Americrest Bank in Oklahoma City, where he chairs the audit committee. He is an attorney, and was previously president, COO and CFO of Goldman Investments.

 

McGrath is CEO of Houston microarray startup Xeotron, which uses micromirror technology for in situ synthesis of arrays. He previously served as president of Sigma-Genosys for nine years, and also served in various sales and marketing roles at Beckman Instruments, Millipore, and Zymark.

 

Both Boatright and McGrath will serve on the board until August, when they will run for election for a one-year term, the company said.


 

William Emhiser has been named president of North American operations for Proteome Systems, the company said June 10.

 

Emhiser will head up the Boston-based subsidiary of the Sydney, Australiacompany, and will manage the close relationship between Proteome and Charles River Proteomics Services, a joint venture between Proteome Systems and Charles River Laboratories; as well as Proteome Systems' relationships with Millipore and Sigma, according to the company.

 

Emhiser comes to Proteome Systems from Millipore, where he was president of the life sciences division. He has also been president of protein separation company Amicon, which was acquired by Millipore in 1996. Before that, he was president and COO of Gelman Sciences, which is now part of Pall.

 

Steven James has been appointed senior vice president, commercial operations of Exelixis, the company said June 10.

 

James comes to Exelixis, of South San Francisco, from Sunesis Pharmaceuticals, where he was chief business officer. He previously held the post of vice president, business development at Isis Pharmaceuticals. He has also worked at Landec, California Biotechnology (now Scios), and Eli Lilly.


 

Robert Monaghan has been named CEO of Zyomyx, the company announced June 9.

 

Monaghan succeeds Lawrence Cohen, who has been CEO and president of the company since 2001. Cohen has been named vice chairman, and will continue to work full time at the Hayward, Calif.-based company.

 

Most recently, Monaghan served as president of Sigma Diagnostics, as well as its subsidiaries, and supervised the sale of the company in 2002. He also has served as a vice president of R&D at Dade Behring, vice president of sales at Behring Diagnostics, and in business development, marketing, and sales positions with SYVA, a division of Syntex Pharmaceuticals, Ciba Corning Diagnostics, Health Charge Corporation, hospital finance consulting group Amherst Associates, and the American Hospital Supply Corporation.


 

Thomas Ingolia has become the new CEO of Myriad Proteomics, based in Salt Lake City, company representatives said last week.

 

Ingolia replaces acting CEO Peter Meldrum.

 

Most recently, Ingolia was working as a consultant for biopharma. Prior to that, he was president of Microbia of Cambridge, Mass. Before that, he held various positions at Ontogeny, based in Cambridge, which subsequently became Curis. He also served in different positions at Eli Lilly.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.